Search

Your search keyword '"Pali-Schöll, I"' showing total 211 results

Search Constraints

Start Over You searched for: Author "Pali-Schöll, I" Remove constraint Author: "Pali-Schöll, I"
211 results on '"Pali-Schöll, I"'

Search Results

1. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

2. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

3. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

4. The ARIA-MeDALL hypothesis

6. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

9. Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI

10. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

11. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

12. Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie : Ein Positionspapier von ARIA, EAACI, AeDA, GPA und DGAKI (Kurzversion)

13. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

14. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

15. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B<

16. Use of biologicals in allergic and type 2 inflammatory diseases in the current COVID-19 pandemic [Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie]

17. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI)

18. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

24. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

25. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

26. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

28. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

29. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

30. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement

31. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

32. Mask 2017: Aria Digitally-Enabled, Integrated, Person-Centred Care For Rhinitis And Asthma Multimorbidity Using Real-World-Evidence

33. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

35. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

36. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

37. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

38. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

39. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)(Clin Transl Allergy (2016) 6 (29) DOI: 10.1186/s13601-016-0116-9)

40. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) (vol 6, 29, 2016)

41. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)(Clin Transl Allergy (2016) 6 (29) DOI: 10.1186/s13601-016-0116-9)

43. Molecular allergen profiling in horses by microarray reveals Fag e 2 from buckwheat as a frequent sensitizer

44. Erratum to : Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

45. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).

46. Abstracts from the Food Allergy and Anaphylaxis Meeting 2016

47. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

48. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

49. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

50. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

Catalog

Books, media, physical & digital resources